Response to Comments: Amniotic and Placental-Derived Product Injections and/or Applications for Musculoskeletal Indications, Non-Wound

Coverage for amniotic and placental-derived product injections/applications for non-wound musculoskeletal indications is determined based on evidence of general acceptance in the medical community, prioritized from peer-reviewed original research, systematic reviews, meta-analyses, consensus statements, and clinical guidelines. Anecdotal or unpublished information has limited influence on coverage decisions, and specific claim-level documentation or frequency limits are not specified in this response summary and require review of the final LCD DL39877.

"Coverage determinations for amniotic and placental-derived product injections or applications for musculoskeletal, non-wound indications are made only when there is evidence of general acceptance i..."

Sign up to see full coverage criteria, indications, and limitations.